Treatment with Next-Generation, Liquid Embolic NeoCast™ is Pain-Free and Leads to Rapid Resorption of Chronic Subdural Hematoma
Arsenal Medical, a clinical-stage company developing innovative biomaterials-based devices, today announced late-breaking data from the EMBO-02 clinical study for NeoCast™, a next-generation, shear-responsive liquid embolic treatment. In EMBO-02, NeoCast was evaluated in patients with chronic subdural hematoma (cSDH), a collection of blood on the surface of the brain, using middle meningeal artery embolization (MMAe). Research presented in podium sessions at the Society of Neurointerventional Surgery (SNIS) annual meeting in Nashville, Tenn., showed that all patients met primary safety and feasibility endpoints. Separate late-breaking results demonstrated that NeoCast can be administered painlessly and resulted in rapid hematoma resorption.
Arsenal Medical Announces Treatment of First Patient with NeoCast™
Arsenal Medical, a leader in the development of biomaterials-based devices for underserved conditions, today announced enrollment of the first patient with the company’s investigational NeoCast™ embolic biomaterial.
